Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 9/20 | 0.52 |
| ▸ | MEN1 | O00255 | 8/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 14/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.50 |
| ▸ | NPY1R | P25929 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5880943 | 0.86 | ACHE (0.44) | KMT2AMEN1MAPTLMNA | |
| SCHEMBL5881036 | 0.84 | KMT2A (0.46) | KMT2AMEN1ALDH1A1L3MBTL1MAPT | |
| SCHEMBL5880988 | 0.82 | ACHE (0.38) | KMT2AMEN1ALDH1A1L3MBTL1MAPT | |
| SCHEMBL5880987 | 0.81 | TACR1 (0.40) | KMT2AMEN1ALDH1A1L3MBTL1MAPT | |
| SCHEMBL5881018 | 0.81 | TACR1 (0.40) | KMT2AMEN1ALDH1A1L3MBTL1MAPT | |
| SCHEMBL5881013 | 0.81 | TACR1 (0.40) | KMT2AMEN1ALDH1A1L3MBTL1MAPT | |
| SCHEMBL5880926 | 0.78 | TACR1 (0.38) | KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL6609995 | 0.78 | ACHE (0.43) | MAPTLMNA | |
| SCHEMBL5880992 | 0.74 | ACHE (0.38) | KMT2AMAPTLMNA | |
| SCHEMBL5880983 | 0.74 | ACHE (0.38) | KMT2AMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7122570-B2 | Tetrahydrocarbazol derivatives as ligands for G-protein-coupled receptors (GPCR) | ZENTARIS AG (DE) | 2006-10-17 | — | — | US | disclosed |
| EP-1453803-A2 | TETRAHYDROCARBOZOLE DERIVATIVES AS LIGANDS FOR G-PROTEIN COUPLED RECEPTORS (GPCR) | Zentaris GmbH (DE) | 2004-09-08 | — | — | EP | disclosed |
| US-20030232873-A1 | Tetrahydrocarbazol derivatives as ligands for G-protein-coupled receptors (GPCR) | ZENTARIS AG (DE) | 2003-12-18 | — | — | US | disclosed |
| WO-2003051837-A2 | TETRAHYDROCARBOZOLE DERIVATIVES AS LIGANDS FOR G-PROTEIN COUPLED RECEPTORS (GPCR) | ZENTARIS GMBH (DE) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232873-A1 | Tetrahydrocarbazol derivatives as ligands for G-protein-coupled receptors (GPCR) | GPR4, GPR88, GPR35 | KMT2A 3412/4885MEN1 2877/4885ALDH1A1 4522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.